David J. Lockhart
Chief Executive Officer chez Transcriptx, Inc.
Profil
David J.
Lockhart was the founder of Ambit Biosciences Corp.
(founded in 2001) where he held the title of President & Chief Scientific Officer in 2005.
He is currently the Chief Executive Officer at Transcriptx, Inc. (since 2014) and the President, Director & Chief Scientific Officer at ReCode Therapeutics, Inc. (since 2022).
In the past, he worked as the Director-Genomics at Novartis Institute for Functional Genomics, Inc. (1999-2000), Vice President-Genomics Research at Affymetrix, Inc., and Chief Scientific Officer at Amicus Therapeutics, Inc. (2006-2013).
Dr. Lockhart obtained his doctorate degree from Stanford University in 1990.
Postes actifs de David J. Lockhart
| Sociétés | Poste | Début |
|---|---|---|
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | President | - |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The private company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Chief Executive Officer | 01/12/2014 |
Anciens postes connus de David J. Lockhart
| Sociétés | Poste | Fin |
|---|---|---|
| AMICUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2013 |
| AMBIT BIOSCIENCES CORP | Founder | 01/07/2005 |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/07/2000 |
| AFFYMETRIX, INC. | Corporate Officer/Principal | - |
Formation de David J. Lockhart
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The private company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Health Technology |
